Pharvaris (NASDAQ:PHVS) Director Elisabeth Bjork Sells 10,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Elisabeth Bjork sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total transaction of $293,200.00. Following the completion of the sale, the director directly owned 15,167 shares of the company’s stock, valued at approximately $444,696.44. The trade was a 39.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $29.68 on Friday. The firm has a 50-day moving average of $28.46 and a 200-day moving average of $26.81. The stock has a market cap of $1.94 billion, a PE ratio of -9.33 and a beta of -2.34. Pharvaris N.V. has a 52-week low of $15.46 and a 52-week high of $33.33.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Equities research analysts predict that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PHVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wolfe Research began coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Citizens Jmp cut their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Royal Bank Of Canada cut their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PHVS. Geode Capital Management LLC raised its stake in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares in the last quarter. Legal & General Group Plc raised its stake in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter. Amundi raised its stake in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.